Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Crager

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Lifetime Data Analysis|July 25, 2020
Extensions of the absolute standardized hazard ratio and connections with measures of explained variation and variable importanceMichael R Crager
Genetic Epidemiology|July 28, 2012
Prospective calculation of identification power for individual genes in analyses controlling the false discovery rateMichael R Crager
Statistics in Medicine|December 5, 2009
Gene identification using true discovery rate degree of association sets and estimates corrected for regression to the meanMichael R Crager
Journal of Applied Statistics|December 15, 2015
Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regressionMichael R Crager, Gong Tang
Journal of Biopharmaceutical Statistics|June 11, 2014
Separate class true discovery rate degree of association sets for biomarker identificationMichael R Crager, Murat Ahmed
Journal of the American College of Cardiology|March 14, 2007
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)Michael J Koren, Michael R Crager, Michael Sweeney
Contemporary Clinical Trials|August 19, 2017
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancerHolly Janes, Marshall D Brown, Michael R Crager, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2020
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast CancerJoseph A Sparano, Michael R Crager, Gong Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Reply to K. Ando et alJoseph A Sparano, Michael R Crager, Gong Tang, et al.
JCO Precision Oncology|May 26, 2021
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific MortalityMichael A Brooks, Lewis Thomas, Cristina Magi-Galluzzi, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Lifetime Data Analysis|July 25, 2020
Extensions of the absolute standardized hazard ratio and connections with measures of explained variation and variable importanceMichael R Crager
Genetic Epidemiology|July 28, 2012
Prospective calculation of identification power for individual genes in analyses controlling the false discovery rateMichael R Crager
Statistics in Medicine|December 5, 2009
Gene identification using true discovery rate degree of association sets and estimates corrected for regression to the meanMichael R Crager
Journal of Applied Statistics|December 15, 2015
Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regressionMichael R Crager, Gong Tang
Journal of Biopharmaceutical Statistics|June 11, 2014
Separate class true discovery rate degree of association sets for biomarker identificationMichael R Crager, Murat Ahmed
Journal of the American College of Cardiology|March 14, 2007
Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)Michael J Koren, Michael R Crager, Michael Sweeney
Contemporary Clinical Trials|August 19, 2017
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancerHolly Janes, Marshall D Brown, Michael R Crager, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2020
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast CancerJoseph A Sparano, Michael R Crager, Gong Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2021
Reply to K. Ando et alJoseph A Sparano, Michael R Crager, Gong Tang, et al.
JCO Precision Oncology|May 26, 2021
GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific MortalityMichael A Brooks, Lewis Thomas, Cristina Magi-Galluzzi, et al.
Pageof 2